(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 8.84%
@ $14.58
Utstedt: 14 feb 2024 @ 15:30
Avkastning: 5.38%
Forrige signal: feb 12 - 20:52
Forrige signal:
Avkastning: 1.02 %
Live Chart Being Loaded With Signals
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors...
Stats | |
---|---|
Dagens volum | 447 000 |
Gjennomsnittsvolum | 494 825 |
Markedsverdi | 775.66M |
EPS | $0 ( 2024-03-14 ) |
Neste inntjeningsdato | ( $-0.870 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.11 |
ATR14 | $0.0560 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Pons Jaume | Buy | 25 846 | Common Stock |
2024-04-16 | Pons Jaume | Sell | 50 000 | Common Stock |
2024-04-16 | Pons Jaume | Sell | 25 846 | Employee Stock Option (right to buy) |
2024-04-04 | Pons Jaume | Sell | 20 000 | Common Stock |
2024-03-14 | Lettmann Jason | Buy | 4 400 | Common Stock |
INSIDER POWER |
---|
87.31 |
Last 97 transactions |
Buy: 3 594 697 | Sell: 591 760 |
Volum Korrelasjon
ALX Oncology Holdings Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
VWE | 0.963 |
NAKD | 0.962 |
AYTU | 0.957 |
SIRI | 0.956 |
IBRX | 0.953 |
TENX | 0.953 |
GSMG | 0.952 |
LAWS | 0.952 |
UTHR | 0.951 |
JAGX | 0.947 |
10 Mest negative korrelasjoner | |
---|---|
NSIT | -0.974 |
OVLY | -0.971 |
SJ | -0.97 |
GXII | -0.967 |
BRIVU | -0.963 |
TETC | -0.961 |
MCAA | -0.961 |
MLTX | -0.961 |
ACVA | -0.961 |
HERA | -0.96 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
ALX Oncology Holdings Korrelasjon - Valuta/Råvare
ALX Oncology Holdings Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-836 000 (0.00 %) |
EPS: | $-3.74 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-836 000 (0.00 %) |
EPS: | $-3.74 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-1.47M (0.00 %) |
EPS: | $-3.03 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-4.52 |
Financial Reports:
No articles found.
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.